Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
P.O. BOX: 14115-154
Department of Genetics
Faculty of Biological Sciences
Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Association of ANRIL Expression with Coronary Artery
Disease in Type 2 Diabetic Patients .
ANRIL is an important antisense noncoding RNA gene in the INK4 locus (9p21.3), a hot spot region associated
with multiple disorders including coronary artery disease (CAD), type 2 diabetes mellitus (T2DM) and many different types
of cancer. It has been shown that its expression is dysregulated in a variety of immune-mediated diseases. CAD is a major
problem in T2DM patients and the cause of almost 60% of deaths in these patients worldwide. The aim of the present study
was to compare the expression level of ANRIL between T2DM patients with and without CAD.
Materials and Methods
In this case-control study, we examined ANRIL expression in peripheral blood mononuclear
cell samples by quantitative reverse transcriptionpolymerase chain reaction (RT-qPCR) in 64 T2DM patients with and
without CAD (33 CAD+ and 31 CADpatients respectively, established by coronary angiography).
Expression analysis revealed that ANRIL was up regulated (2.34-Fold, P=0.012) in CAD+ versus CAD
diabetic patients. Data from receiver operating characteristic (ROC) curve analysis has shown that ANRIL could act as
a potential biomarker for detecting CAD in diabetic patients.
The expression level of ANRIL is associated with presence of CAD in diabetic patients and could be
considered as a potential peripheral biomarker.